Global News

FDA grants accelerated approval for Sirturo for multi-drug resistant TB

Wednesday, January 2, 2013 03:13 PM

The FDA has granted accelerated approval to Janssen Therapeutics’ Sirturo (bedaquiline) tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval is based on the surrogate endpoint of time to sputum culture conversion.

More... »

Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »

The CenterWatch Monthly, January 2013

Wednesday, January 2, 2013 01:39 PM

Parexel celebrates 30 years of change, growth

More... »

Perrigo acquires remaining stake in Cobrek Pharmaceuticals

Wednesday, January 2, 2013 12:18 PM

Perrigo, a global provider of healthcare products, has signed a definitive merger agreement with Cobrek Pharmaceuticals, a Chicago-based, privately held drug development company, and has acquired the company for approximately $45 million on a cash free and debt free basis.

More... »

Parexel acquires Liquent

Wednesday, January 2, 2013 09:49 AM

Parexel International has acquired all of the outstanding equity securities of Liquent, a global provider of Regulatory Information Management (RIM) solutions. Liquent provides an integrated platform of software solutions for regulatory submissions and product registration management, as well as a range of complementary business process outsourcing capabilities.

More... »

Elan completes demerger of Prothena

Friday, December 21, 2012 02:40 PM

Dublin-based Elan has completed the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena. Incorporated in Ireland, Prothena commenced trading on the NASDAQ Global Market as of Dec. 21.

More... »

Synteract to acquire Harrison Clinical Research

Thursday, December 20, 2012 10:37 AM

CRO Synteract, a portfolio company of San Francisco-based Gryphon Investors, has agreed to acquire Harrison Clinical Research (HCR).

More... »

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

Merck, GE Healthcare collaborate on imaging biomarkers for BACE inhibitor program

Wednesday, December 19, 2012 01:18 PM

Merck and GE Healthcare have formed a clinical study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

More... »

Stansfield joins PharmaNet/i3 as executive vice president, clinical operations

Wednesday, December 19, 2012 11:39 AM

PharmaNet/i3, inVentiv Health’s clinical segment and a provider of clinical development services, has appointed Dr. Susan C. Stansfield as executive vice president of clinical operations for phase II-IV development in Europe, Middle East and Africa (EMEA), Asia-Pacific and Latin America. 

More... »